4F3Y
| |
4F3P
| |
4F7D
| |
4FFC
| |
4YS8
| |
4ZR8
| |
6OP0
| Asymmetric hTNF-alpha | Descriptor: | (R)-{1-[(2,5-dimethylphenyl)methyl]-6-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-2-yl}(pyridin-4-yl)methanol, Tumor necrosis factor | Authors: | Arakaki, T.L, Edwards, T.E, Fairman, J.W, Davies, D.R, Foley, A, Ceska, T. | Deposit date: | 2019-04-23 | Release date: | 2019-12-25 | Last modified: | 2024-04-03 | Method: | X-RAY DIFFRACTION (2.55 Å) | Cite: | Small molecules that inhibit TNF signalling by stabilising an asymmetric form of the trimer. Nat Commun, 10, 2019
|
|
5B8F
| |
5BR9
| |
5DLD
| |
5CY4
| |
7TI2
| Structure of KPC-2 bound to RPX-7063 at 1.75A | Descriptor: | 1,2-ETHANEDIOL, Carbapenem-hydrolyzing beta-lactamase KPC, {(3R,7S)-2-hydroxy-3-[2-(thiophen-2-yl)acetamido]-2,3,4,7-tetrahydro-1,2-oxaborepin-7-yl}acetic acid | Authors: | Clifton, M.C, Fairman, J.W, Edwards, T.E, Hecker, S.J. | Deposit date: | 2022-01-12 | Release date: | 2022-10-12 | Last modified: | 2023-10-18 | Method: | X-RAY DIFFRACTION (1.75 Å) | Cite: | Broad-spectrum cyclic boronate beta-lactamase inhibitors featuring an intramolecular prodrug for oral bioavailability. Bioorg.Med.Chem., 62, 2022
|
|
5SCR
| |
5SCW
| |
5SCT
| |
5SD7
| |
5SD0
| |
5SCZ
| |
5SD3
| |
5SD4
| |
5SCP
| |
5SD9
| |
5SDA
| |
5SDB
| |
5SCO
| |